Cargando…
Statement to an Insufficient Systematic Review on Viscum album L. Therapy
BACKGROUND: Up to 88% of oncological patients apply complementary therapies and up to 77% apply complementary mistletoe therapy in the context of integrative oncological approaches. An evidence-based consultation of oncological health professionals regarding complementary therapies used in Germany i...
Autores principales: | Matthes, Harald, Thronicke, Anja, Hofheinz, Ralf-Dieter, Baars, Erik, Martin, David, Huber, Roman, Breitkreuz, Thomas, Bar-Sela, Gil, Galun, Daniel, Schad, Friedemann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049420/ https://www.ncbi.nlm.nih.gov/pubmed/32148549 http://dx.doi.org/10.1155/2020/7091039 |
Ejemplares similares
-
Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients
por: Thronicke, Anja, et al.
Publicado: (2018) -
Cost-Effectiveness of Real-World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer
por: Thronicke, Anja, et al.
Publicado: (2020) -
Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study
por: Oei, Shiao Li, et al.
Publicado: (2019) -
Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer
por: Thronicke, Anja, et al.
Publicado: (2017) -
Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study
por: Thronicke, Anja, et al.
Publicado: (2020)